News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
754,592 Results
Type
Article (45924)
Company Profile (333)
Press Release (708311)
Multimedia
Podcasts (152)
Webinars (25)
Section
Business (213053)
Career Advice (2206)
Deals (37277)
Drug Delivery (144)
Drug Development (84707)
Employer Resources (178)
FDA (17046)
Job Trends (15699)
News (361645)
Policy (34677)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2663)
Accelerated approval (43)
Adcomms (34)
Allergies (169)
Alliances (52228)
ALS (201)
Alzheimer's disease (1785)
Antibody-drug conjugate (ADC) (397)
Approvals (17337)
Artificial intelligence (634)
Autoimmune disease (233)
Automation (50)
Bankruptcy (379)
Best Places to Work (11841)
BIOSECURE Act (22)
Biosimilars (214)
Biotechnology (194)
Bladder cancer (178)
Brain cancer (67)
Breast cancer (702)
Cancer (5459)
Cardiovascular disease (479)
Career advice (1865)
Career pathing (44)
CAR-T (311)
CDC (61)
Celiac Disease (2)
Cell therapy (834)
Cervical cancer (41)
Clinical research (72809)
Collaboration (1997)
Company closure (5)
Compensation (1296)
Complete response letters (83)
COVID-19 (2823)
CRISPR (106)
C-suite (1015)
Cystic fibrosis (154)
Data (7126)
Decentralized trials (3)
Denatured (43)
Depression (160)
Dermatology (58)
Diabetes (571)
Diagnostics (6945)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (309)
Drug pricing (228)
Drug shortages (35)
Duchenne muscular dystrophy (273)
Earnings (93269)
Editorial (66)
Employer branding (21)
Employer resources (158)
Events (122589)
Executive appointments (1069)
FDA (20520)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1649)
Gene editing (224)
Generative AI (58)
Gene therapy (691)
GLP-1 (1136)
Government (4926)
Grass and pollen (7)
Guidances (398)
Healthcare (19256)
HIV (75)
Huntington's disease (53)
IgA nephropathy (95)
Immunology and inflammation (306)
Immuno-oncology (87)
Indications (158)
Infectious disease (3150)
Inflammatory bowel disease (211)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (278)
Interviews (345)
IPO (17096)
IRA (58)
Job creations (4179)
Job search strategy (1563)
JPM (71)
Kidney cancer (19)
Labor market (93)
Layoffs (609)
Leadership (42)
Legal (8582)
Liver cancer (100)
Longevity (29)
Lung cancer (733)
Lymphoma (412)
Machine learning (53)
Management (62)
Manufacturing (963)
MASH (188)
Medical device (13987)
Medtech (14064)
Mergers & acquisitions (21347)
Metabolic disorders (1530)
mRNA (187)
Multiple sclerosis (179)
NASH (21)
Neurodegenerative disease (403)
Neuropsychiatric disorders (108)
Neuroscience (3233)
Neurotech (1)
NextGen: Class of 2026 (6739)
Non-profit (4601)
Now hiring (73)
Obesity (748)
Opinion (323)
Ovarian cancer (187)
Pain (247)
Pancreatic cancer (256)
Parkinson's disease (348)
Partnered (34)
Patents (566)
Patient recruitment (602)
Peanut (64)
People (61819)
Pharmaceutical (95)
Pharmacy benefit managers (36)
Phase 1 (22707)
Phase 2 (31970)
Phase 3 (23936)
Pipeline (7203)
Policy (335)
Postmarket research (2687)
Preclinical (9571)
Press Release (68)
Prostate cancer (280)
Psychedelics (52)
Radiopharmaceuticals (313)
Rare diseases (1051)
Real estate (6419)
Recruiting (72)
Regulatory (26250)
Reports (54)
Research institute (2479)
Resumes & cover letters (374)
Rett syndrome (32)
RNA editing (19)
RSV (93)
Schizophrenia (173)
Series A (275)
Series B (205)
Service/supplier (14)
Sickle cell disease (110)
Special edition (28)
Spinal muscular atrophy (171)
Sponsored (46)
Startups (3846)
State (2)
Stomach cancer (20)
Supply chain (124)
Tariffs (100)
The Weekly (106)
Vaccines (1111)
Venture capital (105)
Weight loss (507)
Women's health (111)
Worklife (20)
Date
Today (124)
Last 7 days (675)
Last 30 days (2803)
Last 365 days (30860)
2026 (8208)
2025 (31086)
2024 (36140)
2023 (40929)
2022 (52114)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36139)
2017 (33569)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (830)
Alabama (91)
Alaska (7)
Arizona (340)
Arkansas (15)
Asia (43400)
Australia (6893)
California (12370)
Canada (3546)
China (1290)
Colorado (528)
Connecticut (525)
Delaware (373)
Europe (93660)
Florida (1884)
Georgia (394)
Hawaii (3)
Idaho (62)
Illinois (978)
India (83)
Indiana (573)
Iowa (22)
Japan (502)
Kansas (130)
Kentucky (44)
Louisiana (40)
Maine (73)
Maryland (1504)
Massachusetts (8884)
Michigan (350)
Minnesota (681)
Mississippi (6)
Missouri (138)
Montana (33)
Nebraska (29)
Nevada (139)
New Hampshire (82)
New Jersey (3318)
New Mexico (31)
New York (3267)
North Carolina (1623)
North Dakota (8)
Northern California (6101)
Ohio (371)
Oklahoma (23)
Oregon (47)
Pennsylvania (2508)
Puerto Rico (27)
Rhode Island (50)
South America (1200)
South Carolina (77)
South Dakota (1)
Southern California (4856)
Tennessee (202)
Texas (1951)
United States (44037)
Utah (372)
Vermont (1)
Virginia (309)
Washington D.C. (81)
Washington State (993)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
754,592 Results for "amkor pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with Trump’s Most Favored Nation policy, patients will suffer.
April 2, 2026
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Pharma Double-Dippers Lead Q1 Deal Activity to Nearly $47B
Deal-hungry Big Pharmas, a long-sought biotech prize, an infrequent buyer and one serial biotech rabblerouser highlight a busy quarter in biopharma M&A.
April 1, 2026
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
In Tight Deal Environment, Pharma May Need To Think Big
The major pharmas are loaded up with trillions in firepower—but are sticking to mid-cap deals. One expert says it might be time to think outside the box and shake up the industry with some consolidation.
March 18, 2026
·
5 min read
·
Annalee Armstrong
Earnings
J&J Reigns as Top Pharma by Revenue While Lilly Leapfrogs on Strong Obesity Sales
While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established itself as the clear leader in the obesity market, in the process capturing investors’ attention and enthusiasm.
March 18, 2026
·
8 min read
·
Tristan Manalac
Patents
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
February 18, 2026
·
4 min read
·
Shawna Williams
Press Releases
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
February 17, 2026
·
4 min read
Press Releases
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 11, 2026
·
6 min read
Mergers & acquisitions
Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts
After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M&A action from other big names, including Novartis, Amgen and AbbVie.
April 3, 2026
·
3 min read
·
Annalee Armstrong
Approvals
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
March 18, 2026
·
3 min read
·
Annalee Armstrong
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
1 of 75,460
Next
